Rytelo (imetelstat) launched in June 2024 as the first-in-class
telomerase inhibitor for lower-risk MDS with transfusion-dependent
anemia. As coverage policies are still being finalized across payers,
this report establishes a baseline of the national payer landscape,
quantifying where Rytelo is covered, how closely payer criteria track
the FDA label, and where access barriers are emerging.